Abstract
BackgroundDue to poor sensitivity, the FDA mandated that rapid influenza antigen (IAT) must be phased out by 2018. At our institution an on-site rapid influenza PCR (PCR) was implemented in emergency departments (ED) at the start of the 2016–2017 influenza season. The purpose of this study was to examine the impact of influenza PCR testing on antimicrobial utilization in the ED.MethodsThis multicenter quasiexperimental study included adults over the age of 50 who were tested for influenza, and discharged from the ED. Subjects were matched 2:1 by age, sex, month of testing, and ED site. The pre-implementation group had IAT (January–April 2016) and the post-implementation had PCR testing (January–April 2017). The primary outcome was antiviral utilization. Other outcomes included diagnostic yield, test turnaround time (TAT), receipt of antibiotics, and 30-day revisit.ResultsThe PCR group of 116 patients (patients) were matched to 232 patients in IAT group (Table 1). Positive results for influenza were reported in 37.9% of PCR vs. 18.1% of IAT groups (P < 0.001); TAT 0.95 (0.75–1.4) hours in PCR vs. 0.60 (0.40–0.85) hours in IAT group (P < 0.001). Oseltamivir was initiated in the ED in 21% of PCR vs. 11% of IAT group (P < 0.001). An additional 28% in PCR group received oseltamivir at ED discharge vs. 15% in IAT group (P = 0.004). Antibiotics were administered in the ED to 8% in PCR group vs. 15% in the IAT group. A positive influenza test was associated with less antibiotic use OR 0.454 (95% CI 0.213–0.967), while abnormal chest radiograph (CXR) and WBC was associated with increased antibiotic use OR 3.667 (95% CI 1.743–7.715). The 30-day revisit was 3.8% and 10.8% in the PCR vs. IAT groups, respectively (P = 0.034).ConclusionReplacing IAT with PCR testing increased diagnostic yield for influenza and receipt of oseltamivir and decreased antibiotic utilization in the ED. Independent predictors for antibiotic use were abnormal CXR and WBC, while positive influenza testing was protective.Table 1: Characteristics of Study PopulationVariablesPCR (n = 116)Antigen (n = 232)P-valueAge59 (53–64)58 (54–65)0.522Male sex50 (43.9)99 (42.9)0.860Symptom duration (days)2 (1–4)2 (1–4)0.870Charlson score1 (0–2)2 (0–4)0.206WBC6.3 (5.2–8.6)6.7 (5.1–8.8)0.739Normal CXR81 (87.1)164 (83.2)0.398Disclosures All authors: No reported disclosures.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.